| ID | 1201 |
| Name of the vaccine | Shigella4V |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Bioconjugate |
| Nucleic acid content | DNA |
| Age | 8 months to 50 years |
| Description of the vaccine | Shigella-tetravalent vaccine. |
| Name of the manufacturer | LimmaTech Biologics AG |
| Name of the manufacturing country | Kenya |
| Year of manufacture | 2022 |
| Clinical Phase status | Clinical - Phase 1, Phase 2 |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Two doses (for adults). Three doses (for children). |
| Mechanism of action | NA |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | With or without Aluminium |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT04056117 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|